Welcome!

News Feed Item

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

Summary

The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug's performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.

A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline.

Scope

- The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
- A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
- In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
- Overview of how innovation products are contributing to the market for SLE therapeutics
- Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
- The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
- First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets

Reasons to buy

The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to -
- Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
- Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
- Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
- Identify the list of first-in-class programs that are potentially open to deal-making opportunities
- Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 The Case for Innovation in Systemic Lupus Erythematosus 7
2.2 Growing Opportunities for Biologic Products 7
2.3 Diversification of Molecular Targets 7
2.4 Innovative First-in-Class Product Developments Remain Attractive 8
2.5 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 8
2.6 Sustained Innovation 8
3 Systemic Lupus Erythematosus 9
3.1 Disease Overview 9
3.2 Epidemiology 9
3.3 Disease Pathophysiology 10
3.4 Disease Symptoms 10
3.5 Environmental and Genetic Predisposition 11
3.6 Diagnosis 11
3.7 Disease Severity Assessments 12
3.7.1 PGA 12
3.7.2 SLEDAI 12

3.7.3 BILAG 13
3.7.4 SRI 13
3.8 Lupus Nephritis 13
3.9 Pharmacotherapy Algorithm 14
4 Clinical and Commercial Landscape 16
4.1 Corticosteroids 16
4.2 Antimalarials 16
4.3 Cytotoxic Chemotherapy 16
4.4 Biologics 17
4.4.1 Benlysta (belimumab) 17
4.5 Comparative Strengths and Weaknesses of Traditional Therapeutics 19
4.5.1 Corticosteroids vs Cytotoxic Therapeutics 19
4.5.2 Comparison of Immunosuppressants: Cyclosporine vs Azathioprine or Cyclophosphamide 21
4.5.3 Cyclophosphamide vs Azathioprine 23
4.5.4 Cyclophosphamide vs Mycophenolate Mofetil 23
4.5.5 Mycophenolate Mofetil vs Azathioprine 23
4.5.6 Biologics vs Immunosuppressants 25
4.6 Current Unmet Needs in the Systemic Lupus Erythematosus Market 27
5 Assessment of Pipeline Product Innovation 28
5.1 Overview of Pipeline Products for Systemic Lupus Erythematosus 28

5.2 Frequently Targeted Molecular Target Families 29
5.3 Comparative Distribution of Programs between the Systemic Lupus Erythematosus Market and Pipeline by Therapeutic Target Family 30
5.4 Comparative Efficacy and Safety of Pipeline Programs 31
5.5 Comparative Distribution of Programs with First-in-Class and Established Targets 33
5.6 Pipeline Programs Targeting Established Molecular Targets 35
5.7 First-in-class Pipeline Programs with Novel Molecular Targets 37
6 First-in-Class Target and Pipeline Program Evaluation 39
6.1 Cytokines and Receptors 39
6.1.1 Pipeline Programs Targeting IFN-? 39
6.1.2 Pipeline Programs Targeting CD74 43
6.1.3 Pipeline Programs Targeting B7 Related Protein 44
6.1.4 Pipeline Programs Targeting IL-21 46
6.1.5 Pipeline Programs Targeting IL-17 49
6.1.6 Pipeline Programs Targeting High Mobility Protein Box 1 51
6.1.7 Pipeline Programs Targeting APRIL 53
6.2 B and T Cell Antigens 55
6.2.1 Pipeline Programs Targeting CD4 55
6.2.2 Pipeline Programs Targeting CD40L 57
6.2.3 Pipeline Programs which Target Fc?R2b (CD32b) 60
6.2.4 Pipeline Programs which Target CD19 62
6.2.5 Pipeline Programs which Target CD22 64
6.3 Intracellular Kinase 67

6.3.1 Pipeline Programs which Target Spleen Tyrosine Kinase 67
6.4 Others 70
6.4.1 Pipeline Programs which Target Immunoproteasome subunit 7 (IMP7) 70
6.4.2 Pipeline Programs which Target ILT-7 71
7 Conclusions 72
8 Deals and Strategic Consolidations 74
8.1 Licensing Agreements 74
8.2 Co-development Deals 76
8.2.1 First-in-Class Developmental Programs Not Involved in Co-development Deals or Licensing Deals 78
9 Appendix 79
9.1 References 79
9.2 Abbreviations 88
9.3 Methodology 89
9.4 Contact Us 89
9.5 Disclaimer 89

List of Tables

Table 1: SLEDAI Index 12
Table 2: Classification of Lupus Nephritis 14
Table 3: Pipeline, Global, First-in-class Modulators of B7-Related Protein, Scientific Assessment 44
Table 4: Pipeline, Global, First-in-Class Modulators of IL-17, Scientific Assessment 49
Table 5: Pipeline, Global, First-in-class Modulators of APRIL, Scientific Assessment 53
Table 6: Pipeline, Global, First-in-class Modulators of CD4, Scientific Assessment 55
Table 7: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Scientific Assessment 60
Table 8: Pipeline, Global, First-in-Class Modulators of CD19, Scientific Assessment 62
Table 9: Pipeline, Global, First-in-Class Modulators of CD22, Scientific Assessment 65
Table 10: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Scientific Assessment 70
Table 11: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Pipeline Development 71
Table 12: Pipeline, Global, First-in-Class Modulators of Immunoglobulin-Like Transcript 7, Pipeline Development 71

List of Figures

Figure 1: SLE, Treatment Algorithm 14
Figure 2: Systemic Lupus Erythematosus, Global, Marketed Products 18
Figure 3: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Marketed Products 19
Figure 4: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 20
Figure 5: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 22
Figure 6: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 24
Figure 7: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety 26
Figure 8: Systemic Lupus Erythematosus, Global Pipeline Overview 28
Figure 9: Systemic Lupus Erythematosus, Global, Pipeline and Marketed Products 30
Figure 10: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Pipeline Programs Relative to Benlysta (belimumab) 32
Figure 11: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Products 34
Figure 12: Systemic Lupus Erythematosus, Global, Pipeline, Programs with Established Molecule Targets 36
Figure 13: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Programs 38
Figure 14: Pipeline, Global, First-in-Class IFN-? Inhibitors, Scientific assessment 41
Figure 15: Pipeline, Global, First-in-Class IFN-? Inhibitors, Pipeline Development 42
Figure 16: Pipeline, Global, First-in-Class CD74 Inhibitors, Pipeline Development 43
Figure 17: Pipeline, Global, First-in-Class Modulators of B7-Related Protein, Pipeline Development 45
Figure 18: Pipeline, Global, First-in-class modulators of IL-21, Scientific Assessment 47
Figure 19: Pipeline, Global, First-in-class Modulators of IL-21, Pipeline Development 48
Figure 20: Pipeline, Global, First-in-Class Modulators of IL-17 , Pipeline Development 50
Figure 21: Pipeline, Global, First-in-Class High Mobility Box Protein 1 Inhibitors, Pipeline Development 52

Figure 22: Pipeline, Global, First-in-class Modulators of APRIL, Pipeline Development 54
Figure 23: Pipeline, Global, First-in-class Modulators of CD4, Pipeline Development 56
Figure 24: Pipeline, Global, First-in-Class Modulators of CD40L, Scientific Assessment 58
Figure 25: Pipeline, Global, First-in-Class Modulators of CD40L, Pipeline Development 59
Figure 26: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Pipeline Development 61
Figure 27: Pipeline, Global, First-in-Class Modulators of CD19, Pipeline Development 63
Figure 28: Pipeline, Global, First-in-Class Modulators of CD22, Pipeline Development 66
Figure 29: Pipeline, Global, First-in-Class Modulators of Spleen Tyrosine Kinase, Scientific Assessment 68
Figure 30: Pipeline, Global, First-in-Class modulators of Spleen Tyrosine Kinase, Pipeline Development 69
Figure 31: Systemic Lupus Erythematosus, Global, Licensing Agreements, 2006–2013 (October) 75
Figure 32: Systemic Lupus Erythematosus, Global, Co-development deals, 2006–2013 (October) 77
Figure 33: Systemic Lupus Erythematosus, Global, First in-Class Programs Not Involved in Co-development or Licensing Deals 78

To order this report: Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Infoblox delivers Actionable Network Intelligence to enterprise, government, and service provider customers around the world. They are the industry leader in DNS, DHCP, and IP address management, the category known as DDI. We empower thousands of organizations to control and secure their networks from the core-enabling them to increase efficiency and visibility, improve customer service, and meet compliance requirements.
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, will describe how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launchi...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, will go over the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, applicatio...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...